From: Pancreatic cancer: Surgery is a feasible therapeutic option for elderly patients
All patients N = 460 | <70 years N = 294 | ≥70 years N = 166 | P value | |
---|---|---|---|---|
Age, years, median (range) | 65 (19-87) | 55 (19-69) | 75 (70-87) | <0.0001 |
Gender | ||||
Male (%) | 214 (47%) | 150 (51%) | 64 (39%) | 0.01 |
Female (%) | 246 (53%) | 144 (49%) | 102 (61%) | |
ASA* score | ||||
1/2 | 195 (42%) | 156 (53%) | 39 (24%) | 0.002 |
≥ 3 | 246 (53%) | 126 (43%) | 120 (72%) | |
Unknown | 19 (5%) | 12 (4%) | 7 (4%) | |
Second primary cancer (per history) | 51 (11%) | 25 (9%) | 26 (16%) | 0.02 |
Jaundice | 160 (35%) | 83 (28%) | 77 (46%) | <0.0001 |
Diagnostic evaluation | ||||
Tomography | 443 (96%) | 285 (97%) | 158 (95%) | 0.5 |
Ultrasound | 149 (32%) | 99 (34%) | 50 (30%) | 0.37 |
Endoscopic ultrasound | 291 (63%) | 197 (67%) | 94 (67%) | 0.73 |
ERCP** | 140 (30%) | 85 (29%) | 55 (33%) | 0.21 |
Preoperative anemia (Hgb < 11 g/dL) | 38 (8%) | 17 (6%) | 21 (13%) | 0.12 |
Tumor site | ||||
Head | 297 (65%) | 173 (59%) | 124 (73%) | 0.004 |
Body/tail | 163 (35%) | 121 (41%) | 42 (27%) | |
Invasive cancer | 293 (64%) | 173 (59%) | 121 (73%) | 0.002 |
Histology | ||||
Ductal adenocarcinoma | 180 (39%) | 105 (36%) | 75 (45%) | 0.2 |
Papillary carcinoma | 44 (10%) | 24 (8%) | 20 (12%) | 0.41 |
Cholangiocarcinoma | 20 (4%) | 14 (5%) | 6 (4%) | 0.38 |
IPMN | 47(10%) | 25 (9%) | 22 (13%) | 0.16 |
MCN | 53 (12%) | 35 (12%) | 18 (11%) | 0.36 |
NET | 33 (7%) | 28 (10%) | 5 (3%) | 0.009 |
Others | 83 (18%) | 63 (20%) | 20 (12%) | 0.1 |